Our open innovation strategy is designed to promote change beyond GSK by sharing expertise, resources, intellectual property and know-how with external researchers and the scientific community.
Our previous focus was on diseases of the developing world, such as malaria, tuberculosis and parasitic infections and, we are now adapting open innovation models to apply to other areas of great medical need and scientific challenge including infectious, autoimmune disease, immuno-oncology and rare diseases.
Our 30-year quest to develop a malaria vaccine
By the time the second hand on your wristwatch has circled its dial, a child in Africa will have died of malaria. And by the time those minutes have added up to a year, more than 500,000 people will have died from the disease. That’s why we have spent the last 30 years trying to develop a vaccine for malaria.
Stevenage bioscience hub
The Stevenage Bioscience Catalyst campus is a major hub for early-stage biotechnology companies
Targeting the immune system through open innovation
We have at least 10 research units focused on immunology across several therapeutic areas and have multiple research programmes underway